Pathway Labs cleared the FDA for six structural heart conditions off one ECG. The $8.5M seed round is the least interesting part of this announcement.
The model trained on 700k+ ECG-echo pairs at NewYork-Presbyterian. In a 3,200-ECG head-to-head, it hit 77% accuracy vs 64% for cardiologists. That gap is real.
Then it landed on OpenEvidence, used by 750k+ verified clinicians. That distribution solves the problem that kills most cardiac AI: getting a busy doctor to actually open the tool.
The multicondition framing also quietly ends the single-indication race. Matching six FDA clearances means assembling six evidence packages. Replication cost just went up.
Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more.
